Eugene

[email protected]

LATEST

Novartis Announces Staff Reductions at Oral Solid-Dose Plant
By

By
Novartis is planning 65 staff reductions at its oral solid-dosage manufacturing facility in Broomfield, Colorado. In October 2017, Novartis announced plans to close the facility, which is owned by its generics…

Rexahn Pharmaceuticals in Cancer Drug Development Pact
By

By
Rexahn Pharmaceuticals, a Rockville, Maryland-headquartered clinical-stage biopharmaceutical company developing therapeutics for treating cancer, has formed a pact with Zhejiang Haichang Biotechnology, a Zhejiang, China-headquartered biopharmaceutical company, to develop Archexin (RX-0201)…

Seattle Genetics, Pieris in Immuno-Oncology Pact Worth up to $1.2 Billion
By

By
Seattle Genetics, a Bothell, Washington-headquartered biopharmaceutical company, and Pieris Pharmaceuticals, a Boston, Massachusetts-headquartered clinical-stage biopharmaceutical company, have partnered to develop multiple targeted bispecific immuno-oncology treatments for solid tumors and blood…

PhRMA Appoints Amgen Chairman and CEO as New PhRMA Chairman
By

By
The Pharmaceutical Research and Manufacturers of America (PhRMA), an industry trade group of innovator, research-based pharmaceutical companies, has appointed three new officers. Robert A. Bradway, chairman and chief executive officer…

Cardinal Health Closes $1.2-billion Divestiture of Distribution Business in China
By

By
Cardinal Health has closed its $1.2-billion divestiture of its Cardinal Health China business to Shanghai Pharmaceuticals Holding, a Shanghai, China-headquartered pharmaceutical manufacturer and healthcare services provider. Cardinal Health announced the…

Teva Announces $17.5-Billion Operating Loss; Restructuring on Track
By

By

FDA Upgrades Status of Pfizer Manufacturing Plant
By

By
The US Food and Drug Administration (FDA) has upgraded the status of Pfizer’s fill/finish manufacturing facility in McPherson, Kansas. Pfizer received a Warning Letter in 2017 following an FDA inspection…

Delmar To Invest $46 Million in Canadian API Manufacturing Plant
By

By
Delmar Chemicals, a LaSalle, Quebec-headquartered manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and other organic fine chemicals, plans to invest $45.8 million to increase production capacity of its LaSalle…

J&J, Theravance Biopharma Partner in Deal Worth up to $1 Billion
By

By
Janssen Biotech, one of the pharmaceutical companies of Johnson & Johnson, has formed a global co-development and commercialization pact with Theravance Biopharma, a South San Francisco, California-headquartered biopharmaceutical company, for…

Novo Nordisk Invests $65 Million to Expand US Finished-Products Mfg Plant
By

By
Novo Nordisk plans to invest $65 million to expand its finished-products manufacturing facility at its Clayton, Johnston County, North Carolina campus. This is the company’s third expansion at the site…